About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID
Irs2
insulin receptor substrate 2
MGI:109334
93 phenotypes from 8 alleles in 12 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background
Annotated Term Reference
Irs2M1Btlr/Irs2M1Btlr
C57BL/6J-Irs2M1Btlr
hyperglycemia J:267533
increased insulin secretion J:267533
Irs2tm1.1With/Irs2tm1.1With
B6.129S6-Irs2tm1.1With
abnormal corpus luteum morphology J:122064
abnormal ovarian follicle morphology J:122064
abnormal ovarian folliculogenesis J:122064
absent mature ovarian follicles J:122064
decreased granulosa cell proliferation J:122064
decreased tertiary ovarian follicle number J:122064
increased atretic ovarian follicle number J:122064
polyovular ovarian follicle J:122064
Irs2tm1Mfw/Irs2tm1Mfw
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
abnormal retina progenitor cell morphology J:98107
decreased total retina thickness J:98107
retina outer nuclear layer degeneration J:98107
retina photoreceptor degeneration J:98107
short photoreceptor inner segment J:98107
short photoreceptor outer segment J:98107
Irs2tm1Mfw/Irs2tm1Mfw
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
abnormal circulating glucose level J:74303
abnormal circulating hormone level J:64791
abnormal circulating insulin level J:94000
abnormal energy homeostasis J:64791
abnormal glucose homeostasis J:64791, J:74303
abnormal lipid homeostasis J:96047
abnormal mating frequency J:64791
abnormal oogenesis J:64791
abnormal ovarian follicle morphology J:64791
abnormal pancreatic beta cell morphology J:96047
absent corpus luteum J:64791
absent estrous cycle J:64791
anovulation J:64791
decreased birth body size J:46134
decreased body weight J:46134, J:74303
decreased circulating estradiol level J:64791
decreased circulating luteinizing hormone level J:64791
decreased circulating progesterone level J:64791
decreased circulating prolactin level J:64791
decreased circulating testosterone level J:64791
decreased gonadotroph cell number J:64791
decreased oocyte number J:64791
decreased pancreatic beta cell mass J:46134, J:135659
decreased pancreatic beta cell number J:94000
decreased primary ovarian follicle number J:64791
decreased skeletal muscle glycogen level J:74303
failure of superovulation J:64791
female infertility J:64791
hyperglycemia J:46134, J:94000, J:96047, J:135659
impaired glucose tolerance J:46134, J:64791
impaired ovarian folliculogenesis J:64791
increased circulating insulin level J:46134, J:135659
increased circulating leptin level J:64791
increased total body fat amount J:64791
insulin resistance J:46134, J:135659
obese J:64791
polydipsia J:46134
polyphagia J:64791
polyuria J:46134
premature death J:46134, J:94000
reduced female fertility J:64791
reduced male fertility J:64791
small ovary J:64791
small pancreatic islets J:96047
small pituitary gland J:64791
small pituitary intermediate lobe J:74303
weight loss J:135659
Irs2tm1Mfw/Irs2tm1Mfw
Tg(Ins2-Irs2)13Mfw/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
abnormal b-wave implicit time J:98107
abnormal cone electrophysiology J:98107
abnormal pancreatic beta cell morphology J:94000
abnormal rod electrophysiology J:98107
decreased a-wave amplitude J:98107
decreased b-wave amplitude J:98107
increased circulating insulin level J:94000
normal mortality/aging J:94000
Irs2tm1Tka/Irs2tm1Tka
involves: C57BL/6 * CBA
abnormal cell differentiation J:68004
abnormal pancreatic beta cell morphology J:65485
abnormal vascular wound healing J:99746
decreased pancreatic beta cell mass J:65485
decreased vasodilation J:99746
normal growth/size/body region phenotype J:65485
hyperglycemia J:99746
impaired glucose tolerance J:65485
increased circulating cholesterol level J:99746
increased circulating free fatty acids level J:99746
increased circulating HDL cholesterol level J:99746
increased circulating insulin level J:65485
increased circulating triglyceride level J:99746
increased insulin secretion J:65485
increased systemic arterial systolic blood pressure J:99746
insulin resistance J:65485, J:99746
Irs2tm1With/Irs2tm1With
Tg(Ins2-cre)25Mgn/0
involves: 129S6/SvEvTac * C57BL/6J
decreased pancreatic beta cell number J:97406
impaired glucose tolerance J:97406
increased body length J:97406
increased body weight J:97406
increased circulating glucose level J:97406
increased circulating insulin level J:97406
increased circulating leptin level J:97406
polyphagia J:97406
Irs2tm1With/Irs2tm1With
Tg(Nes-cre)1Kln/?
involves: 129S6/SvEvTac * C57BL/6 * SJL
abnormal prolactin level J:122064
prolonged diestrus J:122064
prolonged estrous cycle J:122064
Irs2tm1With/Irs2tm1With
Tg(Nes-cre)1Kln/0
involves: 129S6/SvEvTac * C57BL/6J
impaired glucose tolerance J:97406
increased body length J:97406
increased body weight J:97406
increased circulating glucose level J:97406
increased circulating insulin level J:97406
increased circulating leptin level J:97406
increased pancreatic beta cell mass J:97406
increased total body fat amount J:97406
polyphagia J:97406
Irs2tm1With/Irs2tm1With
Tg(Pomc1-cre)1Gsb/0
involves: 129S6/SvEvTac * C57BL/6J
no abnormal phenotype detected J:97406
Irs2tm2Mfw/Irs2tm2Mfw
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA
normal homeostasis/metabolism phenotype J:137845
Irs2tm2Mfw/Irs2tm2Mfw
Tg(Ins2-cre)25Mgn/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
abnormal coat/hair pigmentation J:93415
abnormal pancreatic beta cell morphology J:93415
impaired glucose tolerance J:93415
increased body length J:93415
increased body weight J:93415
increased circulating glucose level J:93415
increased circulating insulin level J:93415
increased circulating leptin level J:93415
increased total body fat amount J:93415
insulin resistance J:93415
polydipsia J:93415
polyphagia J:93415
Irs2tm2Mfw/Irs2tm2Mfw
Tg(Ins2-cre)25Mgn/0
Tg(Ins2-Irs2)13Mfw/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
normal homeostasis/metabolism phenotype J:93415
increased body weight J:93415
Irs2tm2Mfw/Irs2tm2Mfw
Tg(Nes-cre)1Kln/?
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
abnormal glucose homeostasis J:221293
decreased basal metabolism J:221293
decreased oxygen consumption J:221293
impaired glucose tolerance J:221293
increased circulating glucose level J:221293
increased circulating insulin level J:221293
increased circulating leptin level J:221293
increased fasting circulating glucose level J:221293
increased food intake J:221293
insulin resistance J:221293
Irs2tm2Tka/Irs2tm2Tka
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * DBA
normal homeostasis/metabolism phenotype J:137846
increased circulating insulin level J:137846
insulin resistance J:137846
Irs2tm2Tka/Irs2tm2Tka
Tg(Ins2-cre)25Mgn/0
involves: 129S4/SvJae * C57BL/6
decreased pancreatic beta cell mass J:93416
decreased response to leptin J:93416
impaired glucose tolerance J:93416
increased body weight J:93416
increased circulating cholesterol level J:93416
increased circulating glucose level J:93416
increased circulating leptin level J:93416
increased circulating triglyceride level J:93416
increased epididymal fat pad weight J:93416
insulin resistance J:93416
obese J:93416
Tg(Ins2-Irs2)13Mfw/0
involves: C57BL/6
abnormal pancreatic beta cell morphology J:94000
improved glucose tolerance J:94000
increased circulating insulin level J:94000
increased insulin secretion J:94000

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
12/10/2024
MGI 6.24
The Jackson Laboratory